TPG-backed Novotech, a full-service CRO, agreed to merge with PPC Group, a contract research organization. Financial terms were not disclosed. "I am honored to have the opportunity to lead Novotech Holdings as we look to increase the quality and efficiency of our operations and capitalize on the significant growth opportunities across the region. Novotech and PPC are highly complementary CRO platforms, and together we will have unmatched data analytics and insights in the region, as well as bring together a stronger pool of operational talent. This will allow us to better support drug innovation across major markets including China, Korea and other countries in Asia by delivering an end-to-end suite of services that can only be achieved with the combined expertise of Novotech and PPC," John Moller, Novotech Holdings CEO.